Aim: Oxidative stress is associated with progression of chronic liver disease (CLD).
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Introduction
Oxidative stress is increasingly recognized as a key factor in the progression of chronic liver disease (CLD). CLD usually results from hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, alcoholic liver disease, autoimmune hepatitis, primary biliary cirrhosis, and non-alcoholic steatohepatitis. Of these, chronic hepatitis C has been noted as a source of strong oxidative stress 1 , resulting in a high rate of hepatocarcinogenesis among patients with cirrhosis 2 . The liver, a metabolically important organ, is a major reservoir of the mitochondria that serves as the source of reactive oxygen species (ROS). As a result, CLD could represent a major inducer of oxidative stress. In addition, HCV itself induces oxidative stress on hepatocytes 3, 4 .
HCV-induced oxidative stress suppresses production of hepcidin, a negative regulator of iron absorption, thereby resulting in iron deposition. Chronic hepatitis C patients exhibit iron overload in the liver, and the accumulation of iron contributes to increased DNA damage and elevated lipid peroxidation 5, 6 . In addition, chronic hepatitis C patients show significant alteration of the mitochondria, and various HCV proteins elicit the generation of mitochondrial ROS in vitro 3, 7 . Levels of the oxidative stress marker 8-hydroxy-2'-deoxyguanosine are reportedly elevated in the livers of patients with chronic hepatitis C compared to those from patients with other CLDs 2 . The 6 production of 8-OHdG is particularly elevated in patients with HCV-related hepatocellular carcinoma (HCC) 8 . Together, these in vitro and in vivo findings suggest the association of enhanced oxidative stress with chronic hepatitis C.
A major endogenous antioxidant produced by cells is glutathione (GSH). The liver is one of the primary sources of GSH. Hepatic and blood GSH levels are reduced in chronic hepatitis C patients, indicating that anti-oxidative status is attenuated in these patients 5 . Several in vitro experiments suggest that HCV core protein compromises the antioxidant system in the liver, including heme oxygenese-1 and NADH dehydrogenase quinone 1 9, 10 . However, several other groups have reported that antioxidant levels are increased upon expression of HCV core or polyproteins 11, 12 . These seemingly disparate effects could be due to the status of p53, aging, or the presence of other sources of ROS (e.g., inflammation), leading to a greater level of oxidative stress that overwhelms the antioxidant defenses in vivo 13 . Thus, although increased oxidative stress in chronic hepatitis C patients is widely accepted, anti-oxidative conditions in these patients remain unresolved.
The objective of the present study was to investigate the balance between oxidative stress and anti-oxidative stress in patients with chronic viral liver diseases. Serum levels of reactive oxygen metabolites (ROM) were determined as a marker of circulating 7 ROS 14, 15 . The OXY-adsorbent test was also performed to evaluate the corresponding anti-oxidative status 16 . We investigated possible correlations among ROM and OXY values and the clinical parameters and course of CLD in our patient population.
Methods

Subjects
The study group comprised 5 groups. Sciences. After obtaining written informed consent, a detailed medical questionnaire was completed by doctors or dentists.
Blood sample collection and preparation
Fasting blood samples were collected from patients and healthy volunteers. Serum was collected at the time of admission or at the outpatient clinic, meaning that no intervention had been performed before specimen collection. If not assayed immediately, serum aliquots were stored at -80°C until subsequent analysis. The obtained samples were used to determine biochemical data, including serum levels of ROM and OXY.
Measurement of ROM serum levels
Measurement of ROM serum levels was performed using a spectrophotometer (Diacron International, Grosseto, Italy), as reported previously 14 . The measurement unit used was the Carratelli unit (CARR U), where 1 CARR U corresponds to 0.08 mg/dL of hydrogen peroxide.
Measurement of total serum anti-oxidant capacity
In order to determine total serum anti-oxidant capacity, OXY was performed using a spectrophotometer (Diacron International) 16 . This test evaluates the capacity of serum to oppose the massive oxidative action of a hypochlorous acid (HClO) solution. Total anti-oxidant capacity was expressed in terms of HClO (μmol) consumed by 1 mL of sample (μmol HClO/mL).
Calculation of oxidative-anti-oxidative balance
The balance between oxidative stress and anti-oxidative stress was calculated as an 
Statistical analysis
Statistical analysis was conducted using the JMP version 9. were compared using the chi-squared test. Follow-up data were compared using the Wilcoxon signed-rank test. Statistical significance was set at P < 0.05. Univariate analysis was performed in CLD patients to identify factors potentially correlated with oxidative stress-related markers. Age, which is widely accepted as an oxidative stress factor, and any variables yielding P < 0.05 in the univariate analysis were analyzed
Results
Baseline characteristics of the groups
The clinical characteristics of the study groups are shown in Table 1 . No significant differences between HV and CLD groups were seen with regard to age or body mass index (BMI), although the sex distribution and data for multiple clinical parameters did differ significantly between groups (Table 1A) . The clinical characteristics of CLD groups are shown in Table 1B . For further analysis, CLD patients were sorted into subgroups (HBV-nonHCC, HBV-HCC, HCV-nonHCC, and HCV-HCC) depending on viral and HCC status. HBV-nonHCC group patients were younger than the others, but no age differences were apparent between other groups. Sex distribution and BMI were comparable between groups. In HCC-positive groups (i.e., HBV-HCC and HCV-HCC), platelet counts were lower and PT-INR was longer than in nonHCC groups, suggesting splenomegaly and liver reservoir dysfunction in these patients. Among the 49 HCV-nonHCC patients, four patients with lower albumin levels developed HCC during follow-up after examination of oxidative stress-related markers (median, 39 months; Table 1C ).
The follow-up study of HCV-nonHCC (median interval, 16 months) and HCV-HCC (median interval, 17 months) revealed no change in clinical data over these 14 periods (Table 1D) 
Oxidative stress-related markers in CLD patients
Both the oxidative stress marker ROM and calculated oxidative index were significantly higher in patients with CLD than in the HV group; these two groups did not differ significantly in the anti-oxidative stress marker OXY ( Fig. 2A) . Among CLD patients, ROM differed significantly for HCV-nonHCC and HCV-HCC vs. HBV-HCC, OXY differed significantly for HCV-HCC vs. HBV-HCC and HCV-nonHCC, oxidative index differed significantly for HCV-HCC vs. all others (Fig. 2B) .
Oxidative stress-related markers and clinical characteristics
To define the impact of oxidative stress-related markers in CLD, correlations between clinical characteristics and oxidative stress-related markers were analyzed (Table 2A) 
Oxidative stress-related markers in HCV-positive CLD patients
Since HCV positivity correlated with oxidative stress-related markers, we next analyzed stratified data in patients with HCV-related CLD (Table 2B) 
Follow-up of oxidative stress markers in HCV-positive CLD patients
Follow-up data after about one and a half years (median: 16 months for HCV-nonHCC;
17 months for HCV-HCC) were collected from HCV-positive CLD patients (Fig. 4A) .
In HCV-nonHCC, the three oxidative stress-related markers showed no change during follow up. Three patients received pegylated interferon and ribavirin treatment that resulted in sustained viral eradication. Oxidative stress-related markers showed no change in these patients, while two patients showed OXY increase (Fig.   4B ). In HCV-HCC, OXY was increased in the CR group (Fig. 4C,D) .
Follow-up of HCV-nonHCC patients
All HCV-nonHCC group patients were followed for a median of 39 months at our hospital, with four developing HCC. To define whether oxidative stress affects hepatocarcinogenesis, oxidative stress markers were compared between patients who did and did not develop HCC later (Fig. 5) . Although only 4 patients developed HCC later and no significant differences were identified, median OXY tended to be lower than that in patients who did not develop HCC later. ROM is considered to be a reliable indicator of circulating ROS 14, 15 . ROS reportedly induce progression of HCC 18 , inducing the synthesis and activation of a large series of cytokines and growth factors, which in turn lead to malignant transformation 19 .
Discussion
The present results suggest that oxidative stress is increased in HCV-positive patients, particularly those with a high titer of HCV-RNA.
This study also showed that serum levels of ROM were elevated in CLD patients compared to control subjects. These observations indicate that CLD, including that resulting from HBV-positive status, induces increases in systemic ROS. This result is consistent with a previous report demonstrating that HBV X protein induced ROS production in vitro 20 , and with a previous report of increased serum levels of malondialdehyde (an indicator of lipid peroxidation) in HBV-positive patients 21 .
In previous work, we demonstrated that HCC patients with periodontitis had increased levels of ROM, and that patients with advanced HCC had severe Despite this effect, the overall redox environment was oxidative, since the oxidative stress induction was strong enough to overcome the antioxidant power 27 . Adequate oxidative-anti-oxidative balance is expected to be important for improved outcomes of chronic hepatitis C. 
